1536 related articles for article (PubMed ID: 32244180)
1. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
Sanchez-Garrido MA; Tena-Sempere M
Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
[TBL] [Abstract][Full Text] [Related]
2. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Zeng X; Xie YJ; Liu YT; Long SL; Mo ZC
Clin Chim Acta; 2020 Mar; 502():214-221. PubMed ID: 31733195
[TBL] [Abstract][Full Text] [Related]
3. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
[TBL] [Abstract][Full Text] [Related]
4. Androgens and polycystic ovary syndrome.
Nisenblat V; Norman RJ
Curr Opin Endocrinol Diabetes Obes; 2009 Jun; 16(3):224-31. PubMed ID: 19390322
[TBL] [Abstract][Full Text] [Related]
5. A review on inositol's potential in cyclic disturbances of adipose-endocrinology-associated polycystic ovary syndrome.
Almalki WH
Mol Cell Biochem; 2021 Aug; 476(8):2943-2949. PubMed ID: 33755878
[TBL] [Abstract][Full Text] [Related]
6. Polycystic Ovary Syndrome.
Azziz R
Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
[TBL] [Abstract][Full Text] [Related]
7. [Diagnostics of polycystic ovary syndrome].
Lazúrová I; Figurová J; Lazúrová Z
Vnitr Lek; 2015 Dec; 61(12 Suppl 5):5S40-4. PubMed ID: 27124971
[TBL] [Abstract][Full Text] [Related]
8. Androgen signaling in adipose tissue, but less likely skeletal muscle, mediates development of metabolic traits in a PCOS mouse model.
Xiong T; Rodriguez Paris V; Edwards MC; Hu Y; Cochran BJ; Rye KA; Ledger WL; Padmanabhan V; Handelsman DJ; Gilchrist RB; Walters KA
Am J Physiol Endocrinol Metab; 2022 Aug; 323(2):E145-E158. PubMed ID: 35658542
[TBL] [Abstract][Full Text] [Related]
9. Androgen excess and metabolic disorders in women with PCOS: beyond the body mass index.
Condorelli RA; Calogero AE; Di Mauro M; Mongioi' LM; Cannarella R; Rosta G; La Vignera S
J Endocrinol Invest; 2018 Apr; 41(4):383-388. PubMed ID: 28942551
[TBL] [Abstract][Full Text] [Related]
10. Polycystic ovary syndrome in the pediatric population.
Bremer AA
Metab Syndr Relat Disord; 2010 Oct; 8(5):375-94. PubMed ID: 20939704
[TBL] [Abstract][Full Text] [Related]
11. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications.
Diamanti-Kandarakis E
Expert Rev Mol Med; 2008 Jan; 10():e3. PubMed ID: 18230193
[TBL] [Abstract][Full Text] [Related]
12. Polycystic ovary syndrome as a plausible evolutionary outcome of metabolic adaptation.
Dumesic DA; Padmanabhan V; Chazenbalk GD; Abbott DH
Reprod Biol Endocrinol; 2022 Jan; 20(1):12. PubMed ID: 35012577
[TBL] [Abstract][Full Text] [Related]
13. Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction.
González F
Semin Reprod Med; 2015 Jul; 33(4):276-86. PubMed ID: 26132932
[TBL] [Abstract][Full Text] [Related]
14. Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome.
Barrea L; Marzullo P; Muscogiuri G; Di Somma C; Scacchi M; Orio F; Aimaretti G; Colao A; Savastano S
Nutr Res Rev; 2018 Dec; 31(2):291-301. PubMed ID: 30033891
[TBL] [Abstract][Full Text] [Related]
15. Bariatric Surgery Improves Hyperandrogenism, Menstrual Irregularities, and Metabolic Dysfunction Among Women with Polycystic Ovary Syndrome (PCOS).
Christ JP; Falcone T
Obes Surg; 2018 Aug; 28(8):2171-2177. PubMed ID: 29500679
[TBL] [Abstract][Full Text] [Related]
16. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.
Escobar-Morreale HF
Nat Rev Endocrinol; 2018 May; 14(5):270-284. PubMed ID: 29569621
[TBL] [Abstract][Full Text] [Related]
17. The impact of obesity on reproduction in women with polycystic ovary syndrome.
Pasquali R; Gambineri A; Pagotto U
BJOG; 2006 Oct; 113(10):1148-59. PubMed ID: 16827825
[TBL] [Abstract][Full Text] [Related]
18. 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome.
O'Reilly MW; Kempegowda P; Jenkinson C; Taylor AE; Quanson JL; Storbeck KH; Arlt W
J Clin Endocrinol Metab; 2017 Mar; 102(3):840-848. PubMed ID: 27901631
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource.
Azziz R; Kintziger K; Li R; Laven J; Morin-Papunen L; Merkin SS; Teede H; Yildiz BO
Hum Reprod; 2019 Nov; 34(11):2254-2265. PubMed ID: 31751476
[TBL] [Abstract][Full Text] [Related]
20. Androgen excess: a hallmark of polycystic ovary syndrome.
Wang K; Li Y; Chen Y
Front Endocrinol (Lausanne); 2023; 14():1273542. PubMed ID: 38152131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
